Barclays Maintains Overweight on 10x Genomics, Raises Price Target to $22

Benzinga · 2d ago
Barclays analyst Luke Sergott maintains 10x Genomics (NASDAQ:TXG) with a Overweight and raises the price target from $17 to $22.